[
    [
        {
            "time": "2018-04-15",
            "original_text": "AbbVie Inc. Is a Clear Value Play in Biotech Stocks",
            "features": {
                "keywords": [
                    "AbbVie",
                    "value play",
                    "biotech"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Inc. Is a Clear Value Play in Biotech Stocks",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-16",
            "original_text": "Top Analyst Reports for AbbVie, Berkshire & PepsiCo",
            "features": {
                "keywords": [
                    "analyst reports",
                    "AbbVie",
                    "Berkshire",
                    "PepsiCo"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Analyst Reports for AbbVie, Berkshire & PepsiCo",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-17",
            "original_text": "7 Stock Picks With Giant Upside: Goldman",
            "features": {
                "keywords": [
                    "stock picks",
                    "Goldman",
                    "upside"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "7 Stock Picks With Giant Upside: Goldman",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance",
            "features": {
                "keywords": [
                    "J&J",
                    "Q1 earnings",
                    "sales guidance"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance",
                "Correlation": 3,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-19",
            "original_text": "5 Drug Stocks Poised to Surpass on Earnings This Quarter",
            "features": {
                "keywords": [
                    "drug stocks",
                    "earnings",
                    "quarter"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 Drug Stocks Poised to Surpass on Earnings This Quarter",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Shire Sells Oncology Unit Ahead of Takeda's Potential Offer",
            "features": {
                "keywords": [
                    "Shire",
                    "oncology unit",
                    "Takeda",
                    "offer"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Shire Sells Oncology Unit Ahead of Takeda's Potential Offer",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-21",
            "original_text": "Novartis’s 1Q18: Analysts Expect Revenue Growth",
            "features": {
                "keywords": [
                    "Novartis",
                    "revenue growth",
                    "analysts"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis’s 1Q18: Analysts Expect Revenue Growth",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-22",
            "original_text": "Updates on AbbVie’s AndroGel, Lupron, and Kaletra",
            "features": {
                "keywords": [
                    "AbbVie",
                    "AndroGel",
                    "Lupron",
                    "Kaletra"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Updates on AbbVie’s AndroGel, Lupron, and Kaletra",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-23",
            "original_text": "Risankizumab Could Be AbbVie’s Long-Term Growth Driver",
            "features": {
                "keywords": [
                    "Risankizumab",
                    "AbbVie",
                    "growth driver"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Risankizumab Could Be AbbVie’s Long-Term Growth Driver",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "AbbVie’s Imbruvica in 4Q17 and Fiscal 2017",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Imbruvica",
                    "4Q17",
                    "fiscal 2017"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie’s Imbruvica in 4Q17 and Fiscal 2017",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]